The downturn in British factory orders eased only slightly in April, with new export business sliding sharply amid a global ...

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

ONT, which was IP Group’s largest holding at end-2024 (13% of portfolio value), offers a new generation of nanopore-based sensing technology, enabling the real-time, high-performance, accessible and ...

It’s been five years since the U.K.’s breakup with the European Union, and the impacts of extra red tape and rising costs ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

GSK received approval from U.K.'s medicines regulatory body to bring its blood-cancer blockbuster candidate Blenrep back to the market, enabling the British pharma giant to expand its oncology ...

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS? - TRUMP TARIFFS: UK-based drug ...

This publication contains revisions to January 2025 for the first time, while there are also revisions to January 2023 to December 2024 consistent with our GDP quarterly national accounts, UK ...

The MHRA believes this is the first analysis conducted by a UK regulator to ... that despite Lord James O'Shaughnessy's previous evaluation of the UK clinical trial landscape, pharmaceutical and ...

UK stocks stormed higher on Thursday morning ... which now faces combined levies on imports to the US of 125 per cent. But market optimism is tempered by severe uncertainty over the path ahead ...

Mumbai: When the world reeled under President Trump's reciprocal tariff announcement on 3 April, the Indian pharmaceutical industry was relieved as it escaped the initial round of sweeping levies.